Latest International Intelligence
Webinars
The NRDL Conundrum: Balancing Between Access and Pricing for Innovation
May 21, 2025 | 1:00 – 1:45 PM ET
What key insights emerged from the 2024 China National Reimbursement Drug List (NRDL) negotiations and how can they inform strategic go-to-market planning for innovative therapies? In the 2024 NRDL negotiations, only 28% of submitted products passed expert review, significantly raising the bar for entering pricing negotiations.
Sign Up Now
Blog
5 Key Trends in Global Market Access
Key impacts on the market access and payer environment are beginning to unfold from policies enacted in 2023 and new policies enacted in 2024. To gather insights into the latest trends, Trinity Life Sciences conducted interviews with key stakeholders across various pricing and market access landscapes. Trinity is closely monitoring the evolving global advanced therapeutics […]
Read More
White Papers
2023 NRDL Pricing Implementation and Market Access Outcomes Update
The National Reimbursement Drug List (NRDL) negotiations are expected to conclude by November 2024, with pricing outcomes gradually being revealed starting in January 2025. The Trinity Life Sciences team has reviewed the 2023 NRDL inclusion and pricing results, drawing some key learnings.
Read More
Meet Our International Experts
If you have any questions, we’re here to answer them.
We look forward to helping identify solutions for you.